Oncolytics receives patent for method of producing infectious reovirus

By E. Janene Geiss

Philadelphia, May 26 - Oncolytics Biotech Inc. said Friday that it has been granted U.S. Patent No. 7,049,127 entitled "Method of Producing Infectious Reovirus."

The claims describe a method for producing and purifying mammalian reovirus, according to a company news release.

"Effective production methodologies are essential for the development of Reolysin," said Matt Coffey, chief scientific officer of Oncolytics, in the news release.

Oncolytics' clinical program includes a variety of phase 1 and phase 1/ 2 human trials using Reolysin, a proprietary formulation of the human reovirus, alone and in combination with radiation, as a cancer treatment.

The company said this is its 16th U.S. patent.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.